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SUMMARY
Primary stimulation of T cells is believed to trigger unidirectional differentiation from naive to effector
and memory subsets. Here we demonstrate that IL-7 can drive the phenotypic reversion of recently
differentiated human central and effector memory CD8+ T cells into a naive-like phenotype.
These ‘‘naive-revertant’’ cells display a phenotype similar to that of previously reported stem cellmemory
populationsandundergorapiddifferentiationandfunctional responsefollowingsecondarychallenge.The
chromatin landscape of reverted cells undergoes substantial epigenetic reorganization with increased
accessibility for cytokine-inducedmediators such as STAT and closure of BATF-dependent sites that drive
terminal differentiation. Phenotypic reversion may at least partly explain the generation of ‘‘stem cell
memory’’ CD8+ T cells and reveals cellswithin the phenotypically naive CD8+ T cell pool that are epigenet-
ically primed for secondary stimulation. This information provides insight into mechanisms that support
maintenance of T cell memory and may guide therapeutic manipulation of T cell differentiation.
INTRODUCTION
The development of T cell memory is essential for long-term health but it remains uncertain how this
population is maintained over the many decades of human lifespan. Current models of CD8+ T cell differ-
entiation propose a unidirectional and irreversible pathway whereby initial antigen stimulation triggers
sequential differentiation of naive (TN) cells into central memory (TCM), effector memory (TEM), and effector
(TEff) T cells (Klebanoff et al., 2006). T cells gradually acquire increasing effector function but this is associ-
ated with a progressive reduction in the capacity for differentiation and self-renewal, i.e., ‘‘stemness.’’
In settings of persistent antigenic stimulations T cells may progressively lose effector functions and prolif-
erative capacity such that they eventually become exhausted.
Two subsets of phenotypically naive CD8+ T cells with features of memory cells have recently been
described. ‘‘T-memory stem cells’’ (TSCM), which display enhanced capacity for self-renewal and multipo-
tent proliferative potential (Gattinoni et al., 2011), are believed to be minimally differentiated and located
between TN and TCM in the differentiation pathway (Gattinoni et al., 2017). ‘‘Memory T cells with naive
phenotype’’ (TMNP) also exhibit broad polyfunctional capability (Pulko et al., 2016) and are thought to be
functionally imprinted at an early stage of differentiation between CD8+ TN and TCM subsets. Despite
sharing many characteristics, TSCM and TMNP differ in their extended phenotype and it is uncertain if
they represent distinct and stable subsets or derive from a common precursor with phenotypic plasticity.
Although CD8+ TSCM can be produced in vitro by activating TN cells in the presence of interleukin (IL)-7,
IL-21, and the glycogen synthase-3b inhibitor TWS119 9 (Sabatino et al., 2016), the physiological
mechanisms leading to the generation of both these cells and TMNP are largely unknown.
Given the importance of cytokines as key regulators of T cell-mediated immunity, we analyzed the effect of
different cytokines on T cell differentiation after primary stimulation, using T cells from human cord blood
(CB), which are unlikely to have encountered antigen and therefore have a very low frequency of TSCM (Gat-
tinoni et al., 2011). We observed that recently differentiated CD8+ memory T cells can undergo lineage
reversion to a naive-like phenotype when exposed to g-chain cytokines and that these naive-revertant cells
share extensive phenotypic and functional characteristics with both TSCM and TMNP. This work describes a
new pathway of T cell differentiation and provides a unifying theory for the generation of T cells with a
‘‘naive-memory’’ profile.
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RESULTS
IL-7 Induces Recently Differentiated CD8+ Memory T Cells to Revert to a Naive-like
Phenotype
CB mononuclear cells (CBMCs) were activated with anti-CD3 plus IL-2, and the differentiation stage of
CD8+ T cells was evaluated by CD45RA and CCR7 co-expression (Klebanoff et al., 2006). As expected,
activation induced an expansion of TCM (CD45RA
/CCR7+) and TEM (CD45RA
/CCR7-) subsets with a con-
current reduction in TN (CD45RA
+/CCR7+) (Figures 1A and 1B). TEff (CD45RA
+/CCR7-) were not generated
in significant number and were not considered further.
In order to investigate the role of cytokines in determining the fate of recently differentiated memory CD8+
T cells, IL-7 was added to the culture medium when the proportion of CD8+ TN dropped below 20% of the
CD8+ population, typically around 1 week after activation (6.7G 1.9 days, meanG1 SD, n = 50). No further
activation stimulation was given. In the first 3 days following addition of IL-7 the percentage of CD8+ TN
continued to diminish, reaching a nadir of 8.4%G 6.40 (Figure 1B). However, with continuing IL-7 incuba-
tion the great majority of CD8+ T cells started to re-express CD45RA and reverted back to a phenotype
resembling TN and characterized by co-expression of CD45RA, CCR7, CD62L, and CD27 and loss of
CD45RO expression (Figures 1A and S1A). We termed these cells that reverted to a naive-like phenotype
as ‘‘T naive-revertant’’ (TNrev). This re-acquisition of a naive-like phenotype by CD8
+memory T cells reached
a plateau by 13–28 days after initial activation (20 G 4.7 days) and typically represented over 70% of the
CD8+ T cell population (mean 71% G 12, range 45%–95%). As such, this value was only slightly below
the mean of 87% of CD8+ TN at day 0 (G5.8, range 74–98). All samples followed a similar pattern, although
there was variation both in the time taken to reach the peak TNrev level and in the magnitude of the TNrev
population at plateau (Figure 1B). These differences in the percentage of cells with naive phenotype be-
tween day 0 and nadir, and between nadir and plateau, were highly significant (p = 1.99 3 1050 and
p = 2.69 3 1038, respectively, by paired t test).
To demonstrate that the phenotypic reversion of differentiated T cells was not due to selective death or
proliferation of individual T cell subsets, we enumerated the cells within each cell subset and monitored
their proliferation. The total number of all cell subsets before and after reversion remained largely
unchanged (Table S1), and no cell proliferation was detected after the addition of IL-7 and during the
period of phenotypic reversion (Figure 1C). To further confirm that the phenomenon was due to modula-
tion of cellular phenotype, recently differentiated CD8+ TCM and TEM were purified, incubated with IL-7,
and tracked. Phenotype reversion was again demonstrated for over 80% of the purified TCM and TEM
(Figure 1D).
TNrev May Undergo Several Rounds of Differentiation and Reversion
We next assessed whether this property was unique to IL-7 or shared by other cytokines. Recently differen-
tiated CBMCs were incubated with single and multiple combinations of the g-chain cytokines IL-2, IL-7,
IL-15, IL-4, and IL-21. IL-6, an inflammatory cytokine, was also incorporated.
Phenotypic reversion was observed with several of these cytokines, but IL-7 was themost potent agent (Fig-
ure 1E). Interestingly, CD8+ T cells cultured with IL-6 or IL-21 were driven toward a more differentiated
phenotype with a substantial increase in TEff cells. No synergistic effect was observed when IL-7 was admin-
istered together with IL-2, IL-4, or IL-15. In addition, the ability of individual cytokines to promote dediffer-
entiation to TNrev cells was correlated with their ability to maintain CD8
+ T cell survival in vitro (Figure 1F),
whereas IL-6, IL-21, or medium alone led to substantial cell death. This suggests that reversion may be a
default physiological program of recently differentiated CD8+ T cells when a survival stimulus is provided.
Phenotypic reversion also takes place following differentiation induced by mitogenic stimuli other than sol-
uble anti-CD3 (Figure 1G). The percentage of differentiated CD8+ T cells undergoing IL-7-dependent
phenotype reversion after activation with phytohemagglutinin (PHA) and staphylococcus enterotoxin B
(SEB) was similar to those following activation with anti-CD3. Activation with CD3/CD28 beads led to a
smaller proportion of differentiated cells reverting to a naive phenotype, but we were unable to fully re-
move the beads, some of which were still attached to the cells when IL-7 was added, and it is likely that
the resulting continuous antigen stimulation explains the lesser reversion achieved. However, the kinetics
of reversion were similar demonstrating that co-stimulation does not prevent phenotypic reversion.
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We further assessed whether cells could undergo more than one cycle of phenotypic reversion. Since serial
rounds of anti-CD3 stimulation led to a high rate of cell death, PHA was used for two further rounds of acti-
vation, each followed by IL-7 incubation (Figure 1H). Phenotypic reversion was observed after each cycle of
Figure 1. IL-7 Induces Reversion of Recently Differentiated Memory CD8+ T Cells to a Naive-like Phenotype
(A) Flow cytometric analysis of phenotypic changes in CD8+ T cells after activation and successive incubation with 25 ng/mL IL-7. CBMCs were activated with
anti-CD3 plus IL-2, and when the percentage of CD8+ TN dropped below 20%, in this case day 5, cultures were maintained in IL-7. Numbers indicate the
percentage of cells in each quadrant. Single representative experiment out of 50.
(B) Kinetics of phenotype reversion of CD8+ T cells from the 50 different CB samples. Each symbol represents one sample. The shaded area indicates the
interval of time when IL-7 was added for the first time.
(C) CD8+ T cell proliferation after activation and IL-7 administration. CBMCs were stained with CFSE either before activation (left panels) or at day 9, during
phenotype reversion (right panels). At the indicated time points, cell phenotype and CFSE content were assessed for TN (light gray dots) and TCM (dark gray
dots). Dashed lines indicate basal content in CFSE. Single representative experiment out of three.
(D) Flow cytometry evaluation of IL-7-dependent phenotype reversion in recently differentiated TCM and TEM. After activation TCM and TEM were negatively
selected. The two cell subpopulations were then incubated with IL-7 and monitored for phenotype changes over time. Single representative experiment out
of three, for each subset.
(E) The effect of different cytokines on phenotype reversion. CBMCs were activated, and when the percentage of CD8+ TN dropped below 20% the indicated
cytokines were added. The percentage of the cells in the different subsets is shown when the percentage of CD8+ TN reached the nadir (upper panel) and
afterward, when it reached the plateau (lower panel). Data from six samples. Paired t test analysis between the TN levels at nadir and plateau. ** = p < 0.001.
(F) Viability of cells incubated with different cytokines. Activated CBMCs were incubated from day 4 with each cytokine or medium, and CD8+ T cell viability
was evaluated by flow cytometry using 7-AAD uptake. Data are represented as means G 1SD of three samples.
(G) The kinetics of phenotype reversion of CD8+ T cells activated with different artificial stimuli. Data are represented as means G 1SD of three samples.
Paired t test analysis between the TN levels at nadir and plateau. * = p < 0.05, ** = p < 0.001.
(H) The kinetics of phenotype reversion of CD8+ T cells undergoing successive cycles of activation/IL-7 incubation. Newly generated CD8+ TNrev cells were twice
re-stimulated with PHA and induced to revert twice with IL-7 when the percentage of TN dropped below 20%. Single representative experiment out of three.
(I) Flow cytometry analysis of phenotype changes of CD8+ TNrev upon activation with the cognate antigen. CB T lymphocytes were activated, retrovirally
transduced with the SSC-TCR, and induced to revert their phenotype with IL-7 (left panels). Afterward, cells were incubated with peptide-pulsed DCs (central
panels). IL-7 was then added again, driving the transduced cells to revert their phenotype (right panels). Plots were gated on CD8+ T cells. The upper panels
show the percentage of transduced (black dots) and non-transduced (gray dots) CD8+ T cells.
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activation and IL-7 treatment, indicating that CD8+ TN can undergo repeated cycles of differentiation and
reversion.
In order to demonstrate that phenotypic reversion is also possible after activation with cognate antigen,
CBMCs were transduced with a gene encoding a T cell receptor (TCR) specific for a peptide from the
Epstein-Barr virus (EBV) LMP2 protein (Frumento et al., 2013). Following activation and retroviral transduc-
tion, cells acquired a predominantly TCM/TEM phenotype but reverted to TNrev when incubated with IL-7.
Cells were then re-challenged with peptide-pulsed autologous dendritic cells (DCs) and underwent differ-
entiation again to CD8+ TEM within 5 days (Figure 1I). At this point IL-7 was re-added, and after a further
9 days a second reversion to TNrev was attained, demonstrating that phenotypic reversion is also possible
after stimulation with cognate antigen presented by professional antigen-presenting cells.
CD8+ TNrev Proliferate and Differentiate Rapidly into Functional Effector Cells following
Secondary Stimulation
As TNrev are antigen-experienced cells that have previously undergone differentiation and expansion we
were interested to assess their proliferative potential when compared with primary TN. After re-stimulation
TNrev differentiated into memory subsets more rapidly than TN and exhibited a higher proliferation rate
(Figures 2A and 2B). TNrev also rapidly acquired effector function, and when EBV-specific TCR-transduced
TNrev were re-stimulated with peptide-pulsed DCs and driven to a TEM phenotype the cells expressed per-
forin and granzyme B (Figure 2C) and exerted cytolytic activity against target cells (Figure 2D).
T Cells from Cord Blood and Adult Donors Differ in Degree of Reversion and Chromatin
Accessibility
In order to demonstrate that phenotypic reversion phenomenon is not just restricted to T cells from CB we
next enriched CD8+ and CD4+ TN cells from the blood of adult donors and compared their ability to revert
to TNrev following in vitro activation (Figure 2E). Although the vast majority of CB-derived CD8
+ T cells could
be induced to revert to TNrev, this was seen in less than half of naive CD8
+ T cells from peripheral blood (PB)
of adult donors. The reduced degree of reversion in PB cells could not be related to differences in basal
phenotype as these were identical in TN cells fromCB and PB (Figure S1B). Instead, a remarkable difference
was found in the chromatin landscape of TN from the two sources (Figure 2F), which is predicted to influ-
ence a range of biological processes (Figure S2A). Compared with TN from PB, TN from CB showed
increased accessibility to sites binding transcription factors (TFs), in particular those from the basic re-
gion/leucine zippermotif (bZIP) family, of which BATF was the one with the highest number of open binding
sites (Figure 2G). Moreover, TNrev showed more open chromatin regions annotated as regulatory sites for
genes involved in TCR signaling (Figure S2B).
Only recently differentiated TCM and TEM were able to undergo reversion and not established TCM
(CCR7+/CD45RA) and TEM (CCR7
-/CD45RA) CD8+ T cells from adult blood (Figure 2H). This indicates
that, despite similar phenotype, the capacity for IL-7-induced dedifferentiation is observed only within
recently differentiated TCM and TEM and is relatively less efficient in adult donors.
TNrev Phenotype Overlaps with TSCM and TMNP during In Vitro Culture
Using available data (Christensen et al., 2001; Hendriks et al., 2003; Hermiston et al., 2003; Ishida et al.,
1992; Kim et al., 2006; O’Shea et al., 1992; Zehnder et al., 1992) we identified 28 membrane-bound proteins
that exhibit a differential pattern of expression following T cell activation and differentiation. Antibodies
against these proteins were then used to contrast the phenotypic profile of TN and TNrev. The pattern of
expression of integrin b7, CD25, CD127, CD95, CXCR3, and CD49d was found to discriminate between
these two subsets (Figure 3A). Interestingly, CD95 and CXCR3 are also distinct markers of TSCM (Gattinoni
et al., 2011) and CD49d is a marker of TMNP (Pulko et al., 2016). TNrev and TCM are clearly distinguished by
CCR7 and CD45RA expression, but additional differences were also found in the expression of CD25,
CD45RO, CD69, CD95, CD120b, CD122, and PTK7 (Figures 3A and S3). These differences demonstrate
that the phenotypic correlates of reversion extend substantially beyond differential expression of CCR7
and CD45RA.
We next went on to investigate the relationship between TNrev cells and TSCM and TMNP subsets. In partic-
ular we were interested in the stability of the TNrev phenotype and how this could be modulated by culture
conditions. CD8+ TNrev cells had a very similar phenotype to TSCM and TMNP, and all three expressed a
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common profile of CD45RA+/CCR7+/CD27+/CD62L+/CD45RO/CXCR3+/CD31+/CD122lo. Indeed, the
only difference between early TNrev and the other two subsets was that both TMNP and TSCM express the
IL-7 receptor (CD127) and TSCM lack expression of the IL-2 receptor (CD25), whereas TNrev exhibit a
Figure 2. CD8+ TNrev Cells Have Excellent Differentiation and Proliferative Potential and the Amplitude of Reversion Depends on the Cell Source
(A) Flow cytometry analysis of phenotype changes in CD8+ TNrev and TN cells from the same CB sample following stimulation with PHA. Single representative
experiment out of three.
(B) Flow cytometry analysis of the proliferation of CD8+ TNrev and TN cells. Cells from the samples shown in the panel above were stained with CFSE at day
0 and activated with PHA. The CFSE content in the two cell subsets is shown at the indicated time points. Dashed lines represent basal content of CFSE.
Single representative experiment out of three.
(C) Flow cytometry analysis of perforin and granzyme B expression by the re-stimulated TCR-transduced CD8+ TNrev. The intracellular expression of perforin
and granzyme B were assessed in TNrev cells transduced with the SSC-TCR after re-stimulating the cells twice with cognate peptide-pulsed DCs.
(D) Cytotoxic assay of re-stimulated, SSC-specific TCR-transduced TNrev. The T cells were incubated in a standard
51Cr cytolytic assay with target cells
consisting of HLA A*1101-transduced T2 cells loaded with either 1 mg/mL (diamonds), 10 ng/mL (squares) or 1 ng/mL (triangles) of SSC peptide. The peptide
solvent, i.e., DMSO, was used as control (crosses). The percentage of target cell killing at different E:T ratios is indicated.
(E) TN cells were isolated fromCBMCs and PBMCs, activatedwith PHA, and then incubatedwith IL-7. Thepercentageof cells in thedifferent subsets wasmeasuredby
flow cytometry at the indicated time points. Data are represented as meanG 1SD of five CB samples and eight PB samples. Analysis by paired t test.
(F) Differential accessibility of peak regions identified in PB TN cells versus CB TN cells. The x axis indicates Log2 fold change, and the y axis indicates
–Log10 p value of all peaks. Colored points indicate differentially accessible chromatin sites with inaccessible sites as blue and accessible sites as red. Data
are from three CB and three PB samples.
(G) TF-bindingmotif enrichmentsatDACsmoreaccessible inTN fromPBand fromCB.Significant (FDR<0.1)pathwayenrichments identifiedwithinDEG lists fromTNrev.
(H) CD8+ TN, and TCM and TEM, were isolated from adult PB, activated with PHA, and incubated with IL-7 from day 5. The percentage of cells in the different
subsets was measured by flow cytometry at the indicated time points. Data are represented as mean G 1SD of three samples. Paired t test.
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Figure 3. CD8+ TNrev Can Acquire Phenotypic and Functional Characteristics of Other Early Memory T Cell Subsets and Are Present In Vivo
(A) The expression of the markers that discriminate early TNrev from TN and recently differentiated TCM was measured by flow cytometry. Single
representative experiment out of three.
(B) Kinetics of CD25 and CD127 expression by CD8+ TNrev in the presence of either IL-2 or IL-7. After phenotype reversion had occurred, cells were either
maintained in 25 ng/mL IL-7 or switched to culture in 30 U/mL IL-2. The absence of one cytokine led to increased expression of its cognate receptor. The
mean fluorescence intensity (MFI) is shown. Data are represented as meansG 1SD of three samples. Unpaired t test analysis between the MFI levels at day
28, * = p < 0.05.
(C) Kinetics of the expression of discriminatory markers for early TNrev cells. The MFI was measured at different time points during activation and reversion.
Data are represented as means G 1SD of three samples.
(D) Scheme of the differences in phenotype between the memory CD8+ T cell subsets showing naive-like phenotype.
6 iScience 23, 100989, April 24, 2020
CD127lowCD25high phenotype. However, expression of the receptors for IL-7 and IL-2 is down-regulated on
T cells in the presence of their respective cytokines (Minami et al., 1993; Park et al., 2004; Vranjkovic et al.,
2007). When TNrev were deprived of IL-7 and maintained in IL-2 for 2 weeks they adopted a phenotype
almost indistinguishable from TSCM and TMNP with rapid decrease in CD25 expression and progressive
increase in CD127 expression (Figure 3B). After an additional 2 weeks of culture with IL-2 there was further
progressive loss of CD49d, CD95, CXCR3, and integrin b7 (Figure 3C) such that late TNrev acquire a pheno-
type approaching that of primary TN, although their epigenetic signature clearly identifies them as a
different population. We were unable to monitor the cells further due to increased cell death. These results
suggest that the cytokine milieu and the time since activation account for the modest phenotypic diversity
between TNrev, TSCM, and TMNP (Figure 3D). TNrev also share functional characteristics with TMNP as the latter
cells express granzyme B and secrete IFNg and TNF-a after re-stimulation with phorbol myristate acetate
(PMA) plus ionomycin (Pulko et al., 2016). Resting TNrev also became polyfunctional after the same treat-
ment, r (Figure 3E).
To assess the in vivo relevance of phenotypic reversion we also looked for the presence of cells with the
TNrev signature in the blood and secondary lymphoid tissue (tonsils) of adult donors. CD8
+ T cells with a
CCR7+CD45RA+ naive phenotype and expression of CD95 and integrin b7 were present within tonsil but
were not seen in blood (p = 0.017, unpaired t test, Figure 3F). The population of memory T cells within tonsil
had a CD95low and integrin b7 phenotype (Figure S4) and was clearly distinguishable from the putative
TNrev.
Substantial Chromatin Reorganization Is Observed during Differentiation from TN to TEM and
This Is Partially Retained following Reversion
Epigenetic modifications have a profound regulatory influence on CD8+ T cell differentiation and function
(Henning et al., 2018; Moskowitz et al., 2017). We next used ATAC-seq to investigate the profile of chro-
matin landscape remodeling during T cell differentiation and reversion. ATAC-seq analysis was performed
on purified TN, TCM, TEM, and TNrev CD8
+ populations following in vitro culture. ATAC-seq read density
profiles at phenotype-defining genes such as CCR7 and GZMB were compatible with lineage-specific
expression (Figure S5).
Differentially accessible chromatin sites (DACs) were identified within memory subsets and contrasted with
the profile in naive cells (Figures 4A and S6A). The majority of epigenetic modifications were acquired rela-
tively late in differentiation during transition from TCM to TEM. In particular, only 26 DACs developed during
transition from naive to central memory cells but this increased markedly to 5,829 with further differentia-
tion to TEM. Interestingly, 51% of these DACs were lost during reversion to TNrev but 2,830 DACs still
remained within TNrev cells (Figures 4A and 4B). Read density distributions at TEM and TNrev DACs further
indicate that the chromatin landscape of TNrev cells retains similarity to TEM cells (Figures 4C and 4D) and is
supported by principal component analysis of sample-wise chromatin accessibility, which identified unique
groups for the TN, TCM, and TEM populations and alignment of TNrev with thememory subtypes (Figure S6B).
We next investigated the balance of open and closed chromatin during differentiation and reversion. A
relative increase in the number of inaccessible chromatin regions was observed during differentiation
with 4,316 closed and 1,299 open DACs in TEM compared with TN (Figure 4E). This profile was retained
within the TNrev population with values of 2,194 and 617 DACs, respectively. The great majority of DACs
within TNrev were shared with the TEM population, although 216 and 546 regions were uniquely open
and closed, respectively, within this subtype.
Biochemical Pathways Associated with Reversion Can Be Identified by Epigenomic and
Transcriptional Analysis of T Cell Subsets
In order to examine the relationship between chromatin landscape and gene expression, DAC regions
were next annotated with the gene whose transcriptional start site was nearest to the peak summit.
Figure 3. Continued
(E) TNrev were re-stimulated with PMA plus ionomycin, and the percentages of cells expressing granzyme B, IFNg, TNF-a, and combinations thereof were
measured after 3 and 14 h. Data are represented as mean of three samples.
(F) Cells with the TNrev signature are present among the TN from tonsils, but not from PB. The expression of CD95 and integrin b7 was measured gating
CCR7+/CD45RA+ CD8+ T cells from tonsils of seven patients with recurrent acute tonsillitis or from PB of seven unrelated healthy individuals.
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Figure 4. Chromatin Landscape Changes during Differentiation from TN to TCM and TEM and Reversion to TNrev
(A) Pairwise comparisons of chromatin accessibility at peak regions. The x axes indicate Log2 fold change, and the y axes
indicate unadjusted –Log10 p value of all peaks. Colored points indicate differentially accessible chromatin sites with
inaccessible sites as blue and accessible sites as red.
(B) DACs count for accessible and inaccessible regions in comparison with TN are shown for TCM, TEM, and TNrev.
(C) Tracking from TN to TNrev the accessibility of DACs becoming inaccessible (TN to TEM closing)/accessible (TN to TEM
opening) upon differentiation to TEM.
(D)Tracking from TN to TNrev the accessibility of DACs becoming inaccessible (TN to TNrev closing)/accessible (TN to TNrev
opening) upon reversion to TNrev. The y axis is chromatin accessibility in units of rlog normalizedmapped reads at the peak
site.
(E) Overlaps of differentially accessible sites. Overlaps of DACs more accessible in TCM/TEM/TNrev compared with TN (left)
and DACs less accessible in TCM/TEM/TNrev compared with TN (right).
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As anticipated, differential chromatin accessibility was observed at genes encoding phenotypic markers
that discriminate T cell subsets including CD25, CD127, integrin b7, and CXCR3 (Figure 5A).
Genomic regions enrichment of annotations (GREAT) analysis (Table S2) revealed that the 1,648 DAC sites
that became closed in TEM, and were not reopened in TNrev, were enriched for pathways related to TCR
signaling in naive T cells and CXCR4-mediated signaling. Sites that were opened during reversion of
TEM to TNrev showed enrichment for IL-7 signal transduction and Lck/Fyn-mediated initiation of TCR
activation, whereas the 546 DAC sites uniquely closed in TNrev were enriched for pathways involved in
generation of T cell cytotoxicity.
To further interrogate the differences between true TN and TNrev cells we combined DAC analysis with tran-
scriptional analysis of the two populations. In total 2,830 DAC regions had been identified between the two
subtypes, 622 of which were more accessible in TNrev and 2,208 less accessible (Figure 5B). These regions
were annotated with the gene whose transcriptional start site was nearest to the peak summit. Pathway
enrichment analysis with g:Profiler highlighted that genes becoming less accessible in TNrev included those
that regulate the major differentiation pathways for Th1, Th2, and Th17 cells (Figure 5C). Genes associated
with retinol metabolism became markedly more accessible in TNrev and is of note given the pleiotropic
Figure 5. Chromatin Accessibility Identifies Biochemical Pathways Specific for TN and TNrev
(A) ATAC-seq signal tracks at selected markers that discriminate early TNrev from TN and recently differentiated TCM. Gene diagrams (bottom) show
alternative transcripts with black boxes indicating exons. Each subset signal is aggregated across the constituent samples, n = 4(TN), 3(TCM), 3(TEM), 4(TNrev).
The y axes are in units of reads per million mapped reads.
(B) DAC sites in TNrev versus TN cells. Normalized mapped read density (RPKM) of aggregated TN (n = 4) and TNrev (n = 4) mapped ATAC-seq reads at
differentially accessible chromatin sites (centered on peak summit, extended +/ 5 kbp).
(C) Pathways significantly enriched (adjusted p value <0.1) in genes closest to TN accessible or TNrev accessible DACs.
(D) Efficiency of reversion in the presence of ATRA. The percentage of CD8+ TNrev was recorded at day 24 from activation in three CBMC samples. Unpaired t
test.
(E) After activation CBMCs were incubated with the indicated combination of IL-7 25 (ng/mL), ATRA (108M), and BMS (493 3 3 106M). Data are from three
CBMC samples. One-way ANOVA.
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effects on retinoic acid on T cell differentiation (Beijer et al., 2013). Indeed, escalating doses of all-trans ret-
inoic acid (ATRA) progressively inhibited reversion of IL-7-treated CD8+ T cells (Figure 5D) and this was
blocked by a pan-retinoic acid receptor antagonist (Figure 5E).
Transcriptional analysis confirmed that RNA expression levels were strongly associated with ATAC-seq
read density at transcription start sites and enhancer regions (Figure 6A), and enrichment analysis of
gene sets annotated at TNrev DACs confirmed strong relationship between chromatin accessibility and
expression level (Figure 6B). Transcriptome analysis revealed 2,841 differentially expressed genes
including major immune regulators such as FOS, JUN, KIT, and IL2RA (Figures 6C and 6F and Table S3).
Moreover, 32 of the 104 genes within the Notch signaling pathway were differentially regulated in TNrev
(Figures 6D and 6G). Gene set enrichment analysis (GSEA) of regions closest to Notch signaling genes
confirmed an enrichment in accessible chromatin regions in TNrev cells (Figure 6E) particularly in the
HDAC2 and HDAC9-associated regions.
Comparative transcriptional analysis of TNrev with memory T cells (TMem) (Figures S7A–S7C) also confirmed
RNA expression to be associated with ATAC-seq read density (Figure 6F), and pairwise comparison
Figure 6. Chromatin Accessibility and Transcriptome Profiles of TN and TNrev
(A) Averagemapped read density profiles (centered on TSS (top) and enhancer regions (bottom) generated from aggregated TN (left) and TNrev (right) ATAC-
seq reads. Profiles are for genes identified from transcriptome analysis to be expressed at low, medium, and high levels in TN and TNrev cells, respectively.
(B) Enrichment score (ES) for gene expression changing coordinately with chromatin accessibility. ES of genes closest to TNrev accessible (red) and TN
accessible (green) DACs, vertical bars indicate position of such genes on the axis of fold change in expression (ranking frommost down-regulated in TNrev to
most up regulated in TNrev).
(C) Microarray analysis was performed on three CD8+ TN samples and on the respective CD8
+ TNrev cells. Pairwise comparison of gene expression in TN
versus TNrev cells showing –Log2 p value versus Log2 fold change of all genes. Colored points indicate differentially expressed genes that are down-regulated
in TNrev (blue) and up-regulated in TNrev (orange).
(D) The genes in the Notch pathway (yellow dots) that are significantly down-regulated and up-regulated in TNrev are labeled.
(E) Barcode plot from GSEA analysis showing ES of Notch signaling genes within sites ranked by chromatin accessibility. Vertical bars indicate position of
such genes on the axis of fold change in chromatin accessibility, ranking from most inaccessible in TNrev to most up accessible in TNrev.
(F) As in (A) but for aggregated TNrev (left) and TMem (right) ATAC-seq reads.
(G) RNA-seq analysis was performed on four TMem samples (two TCM and two TEM) and on the respective CD8
+ TNrev cells. Pairwise comparison of gene
expression in TN versus TNrev cells showing –Log2 p value versus Log2 fold change of all genes. Colored points indicate differentially expressed genes that are
down-regulated in TNrev (blue) and up-regulated in TNrev (orange).
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revealed 447 genes down-regulated in TNrev including several involved in T cell cytolytic activity such as
GZMB, GZMH, and GNLY. In contrast, 267 genes were up-regulated and included proteins that support
cell survival and act to block cell differentiation, such as CISH, NPDC1, HSF4, and OSM (Figure 6G). Inter-
rogation of the transcriptomes of TNrev, TMem, and TN subsets allowed identification of 97 signature genes
specific for TNrev (Figures 7A and 7B) and pathways enriched in genes that were differentially regulated in
this subset (Figure 7C). These include a number of intracellular signaling pathways, such as JAK-STAT and
the RUNX-dependent regulation of WNT signaling. Comparison of TF transcripts in TNrev and TMem
(Figure S8) showed differences in the expression of TFs related to stemness and generation of TSCM
(Gattinoni et al., 2012; Kondo et al., 2018).
Reversion Is Associated with Opening of Binding Sites for RUNX and STAT Transcription
Factors and Closure of Sites that Bind BATF
TFs can instigate chromatin remodeling and act as important regulators of differentiation. As such, we next
assessed the relative enrichment of TF-binding motifs within genomic regions that became differentially
open or closed in the different cell subsets. DACs that became more accessible in TEM were enriched in
binding motifs for five TF complexes, including PU.1/IRF, COUP-TFII, and zinc finger members, and these
open sites were largely retained during reversion to TNrev cells (Figures 7D and 7E). In contrast, many
TF-binding motifs became less accessible upon differentiation to TEM although this profile was not strongly
retained in the TNrev subset.
Finally, in order to gain insight into the potential regulators of reversion we focused on the relative access of
TFs for regions of chromatin that were uniquely open or closed in TNrev cells. Strikingly, chromatin regions
containing binding motifs for ET1, RUNX1, and RUNX2, as well as STAT1, STAT4, and STAT5, all became
more accessible during reversion, although transcriptional activity from RUNX1 and RUNX2 genes was sup-
pressed in the revertant population (Figure 7F and Table S4). In contrast, there was substantial closure of
chromatin regions containing binding motifs for BATF and ZNF189 (Figure 7G and Table S4), which is of
particular note given the importance of BATF in driving PD-1-mediated T cell exhaustion (Wherry, 2011).
DISCUSSION
There is increasing appreciation of the importance of cellular plasticity (Blanpain and Fuch, 2014), and
reversion of mature cells into stem cells has been confirmed in some organ systems (Stange et al., 2013;
Tata et al., 2013). Here we show that extensive phenotypic reversion of effector CD8+ T cells to naive pheno-
type can occur within the human immune system. Reversion was mediated primarily by IL-7, which is ex-
pressed by a range of stromal cells within secondary lymphatic organs and is therefore available to support
reversion following local antigen-driven activation (Huang and Luther, 2012). Indeed, cells with a TNrev
phenotype were located within human tonsil. An interesting observation was that the addition of IL-7 mark-
edly decreased apoptosis, suggesting that reversion may be a ‘‘default’’ pathway of recently activated TN
cells in the presence of appropriate survival signals (Hong et al., 2012; Mackall et al., 2011; Surh and Sprent,
2008).
The finding sheds light on the potential relationship between the TSCM, TMNP, and TNrev populations. These
three groups share a common core phenotype exemplified by expression of CD45RA, CCR7, and CXCR3.
CD45RA regulates the signaling threshold in T lymphocytes (Hermiston et al., 2003; Irles et al., 2003), and
CCR7 permits entry into secondary lymphoid tissue, whereas CXCR3 plays a fundamental role in extrava-
sation of CD8+ T cells into inflammatory sites (Cole et al., 1998; Mikucki et al., 2015; Peperzak et al., 2013).
Figure 7. Transcriptional Signatures of TNrev Cells
(A) Intersections of DEGs identified from differential expression analysis of TNrev versus TMem and TNrev versus TN.
(B) Heatmap of the top 40 TNrev signature genes. Z-scores were calculated for each gene from RNA-seq (left) and Microarray (right) datasets independently.
(C) Significant (FDR<0.1) pathway enrichments identified within DEG lists from TNrev versus TMem and TNrev versus TN.
(D) TF-binding motif enrichments at DACs more accessible compared with TN. Motif enrichments were calculated on the following DACs: 4 shared in TCM,
TEM and TNrev; 890 in TEM; 401 shared in TEM and TNrev; 216 in TNrev.
(E) TF-binding motif enrichments at DACs less accessible compared with TN. Motif enrichments were calculated on the following DACs: 14 shared in TCM,
TEM, and TNrev; 2,868 in TEM; 1,648 shared in TEM and TNrev; 546 in TNrev.
(F) Expression of TFs with binding motifs enriched in loci that are uniquely open in TNrev cells. The x axis indicates fold change in TF expression, and the y axis
indicates -log10 p value of TF-binding motif enrichment in loci uniquely more accessible in TNrev cells. Increasing dot size indicates increasingly significant
difference in TF expression and color indicates TF family.
(G) As in (D) but for TFs with binding motifs enriched in loci uniquely closed after reversion to TNrev.
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The naive-memory phenotype therefore generates an antigen-specific memory pool, which retains the
ability to enter lymphoid tissue but has developed heightened responsiveness to re-challenge and may
gain rapid access to tissue sites.
Interestingly, the major differences in the phenotype of TNrev, TSCM, and TMNP relate to expression of the
IL-7 and IL-2 receptors and these were modulated on TNrev according to the local concentration of IL-2 and
IL-7 (Minami et al., 1993; Park et al., 2004; Vranjkovic et al., 2007). TSCM also express CD95
+, whereas TMNP
express CD49d, and we observed that both receptors are down-regulated during prolonged incubation,
with CD95 expression falling more rapidly than CD49d expression. As such, we would suggest that the
three populations represent a spectrum of naive-memory cells that are generated by reversion and display
modest phenotypic diversity that varies according to cytokine concentration and time since activation.
Indeed, phenotypic transition of TEM to TCM populations has been observed in murine systems (Wherry
et al., 2003), and reversion from TEM to TCM and from these subsets to TSCM was described in patients
following hematopoietic stem cell transplant (Cieri et al., 2015).
This work builds on the work of Cieri et al. who previously demonstrated the generation of TSCM from naive
cells after T cell engagement in the presence of IL-7. However, in that study the cytokine was included in
culture from the start of activation. We certainly do not rule out the possibility that TMNP and TSCM may
also be generated by additional mechanisms such as direct differentiation from TN (Cieri et al., 2013; Lugli
et al., 2013; Sabatino et al., 2016; Zanon et al., 2017) and CD8+ TSCM have also been induced in vitro by acti-
vation of T cells in the presence of a glycogen synthase-3b inhibitor (Sabatino et al., 2016). Engagement of
the Notch pathway in memory T cells also generates TSCM-like CD8
+ and CD4+ T cells (Kondo et al., 2017),
and we found a number of genes in the Notch pathway to be differently expressed between TN and TNrev
(Figure 6D). Furthermore, IL-7 can further enhance with Notch signaling to induce a TN-like phenotype in
recently activated CD8+ T cells (Kondo et al., 2018). These findings suggest that notch engagement and
IL-7 may represent two alternative mechanisms to generate TSCM-like cells.
Importantly, we observed that TNrev cells were able to undergo several rounds of reversion in vitro, and as
such this process may be important in protection from both acute and chronic infectious agents. Indeed, it
is now clear that a substantial proportion of antigen-experienced T cells is contained within the apparent
‘‘naive’’ CD8+ T cell pool (Ellefsen et al., 2002; Remmerswaal et al., 2012). Longer-term culture of TNrev led to
progressive down-regulation of integrin b7 and CXCR3, but it is uncertain if they can ultimately acquire a
phenotype indistinguishable from that of primary TN.
Most of our work was performed on T cells from CB, which contains very few memory or effector cells. We
did observe phenotypic reversion using TN cells from adult donors, although the relative proportion of cells
that underwent reversion was sharply reduced and may reflect the decreased number of open chromatin
sites and binding sites for TF in adult PB. Interestingly, the epigenetic landscape of CD8+ T cells in older
people is globally biased toward a differentiated phenotype (Moskowitz et al., 2017) with a reduction in
chromatin accessibility that is most apparent at the IL-7R locus (Ucar et al., 2017).
Phenotypic reversion may help to explain the paradox of preservation of the human TN pool during aging
despite in vivo analyses and mathematical modeling suggesting that thymic output is insufficient for its
maintenance (den Braber et al., 2012; Hakim et al., 2005; Murray et al., 2003). Interestingly, it was found
that the TSCM/TN ratio in PB increases with age (Li et al., 2019), suggesting that during aging naive-memory
cells replace TN and sustain immunological memory.
Epigenetic regulation maintains the equilibrium between self-renewal and differentiation of stem cells and
regulates tissue homeostasis throughout life. As such we were keen to understand how the chromatin land-
scape was modified following T cell activation and if these changes were reversible during phenotypic
reversion to TNrev. Interestingly, this was largely not the case and TNrev cells retained an epigenetic profile
that was similar to effector cells. As such, TNrev become ‘‘epigenetically primed’’ for secondary activation at
the same time as they undergo phenotypic reversion to a naive-memory phenotype. The chromatin mod-
ifications within TNrev are likely to explain their ability to rapidly differentiate and acquire effector function in
response to secondary stimulation and reveal a discrepancy between the degree of phenotypic and epige-
netic reversion. This may partly explain the decrease in chromatin accessibility in phenotypically naive
CD8+ T cells in older people (Ucar et al., 2017). Furthermore, the observation that the chromatin landscape
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of TNrev is much more extensively modified than that of TCM provides further confirmation that they have
undergone sequential differentiation and reversion rather than minimal differentiation from TN.
Analysis of the distribution of TF-binding sites within differentially accessible chromatin regions can help to
identify potential transcriptional regulators of differentiation. A striking observation was that many chro-
matin regions containing binding sites for BATF became closed during reversion. BATF is an essential
regulator of CD8+ differentiation (Kurachi et al., 2014), and PD-1 engagement on T cells can drive
BATF-dependent terminal differentiation (Quigley et al., 2010).
Reversion may play a potential role in limiting T cell exhaustion in both physiological and pathological set-
tings, and it is noteworthy that the chromatin region containing the IL-7R gene becomes poorly accessible
in exhausted CD8+ cells (Scott-Browne et al., 2016). In contrast, chromatin regions enriched for binding
sites of several TFs, including RUNX, STAT, and ETS family members, becamemore accessible within rever-
tant subsets. Stat1 and Stat4 signaling regulate T cell responses to interferon and cytokine signaling (Gil
et al., 2006; Nguyen et al., 2002; Thierfelder et al., 1996), STAT5 is critical in maintaining effector CD8
T cell responses (Tripathi et al., 2010), and over-representation of ETS motifs in chromatin accessible
regions has been observed previously in naive T cells (Moskowitz et al., 2017). As such the ‘‘epigenetic prim-
ing’’ of naive-memory subsets appears to reflect an increased sensitivity to interferon and cytokines within
the local microenvironment but protection from terminal differentiation.
Cytokine-driven reversion of recently activated CD8+ T cells thus uncovers a novel pathway for T cell differ-
entiation and provides a unifying hypothesis for the existence of a naive-memory pool that contains TSCM,
TMNP, and TNrev populations. We also show that the chromatin structure of naive-revertant cells is substan-
tially reorganized in comparison with the naive pool and as such they are epigenetically ‘‘primed for
secondary activation. These observations will help to guide studies of fundamental mechanisms that regu-
late T cell differentiation and should also be of considerable value for optimal generation of naive-memory
cells for adoptive T cell immunotherapy as less differentiated cells have been associated with superior
engraftment, persistence, and antitumor activity (Hinrichs et al., 2011; Klebanoff et al., 2011).
Limitations of the Study
A few limitations should be considered when interpreting our data. Although we identified cells with the
phenotype of TNrev cells in human tonsil, it will be of interest to assess further if these are generated directly
in vivo. In addition, it will be important to pursue parallel studies within animal models to interrogate po-
tential mechanisms of phenotypic reversion.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
DATA AND CODE AVAILABILITY
All relevant data are available from the authors upon request. RNA sequencing data have been deposited
in Gene Expression Omnibus, accession number GSE114812.
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ACKNOWLEDGMENTS
We thank Yvonne Caffrey and the staff of the NHS Cord Blood Bank, Colindale, UK, for providing CB units;
Richard Brain and the staff of the Blood Donor Center, NHSBT, Birmingham, UK, for providing blood sam-
ples; and David Briggs and the staff of Cellular and Molecular Therapies, NHSBT, Birmingham, UK, for lab-
oratory support. We thank Steve Lee for providing the construct for TCR gene transduction and Paul Murray
and Eszter Nagy for providing mononuclear cells from tonsils. We also thank Peter Cockerill, Sarah Beving-
ton, and CelinaWhalley for suggestions on ATAC sequencing. We are grateful to Dr Geoff Brown for advice
on the use of ATRA. RNA-seq was carried out by Edinburgh Genomics, The University of Edinburgh, Edin-
burgh, UK. Genomics is partly supported through core grants from NERC (R8/H10/56), MRC (MR/K001744/
1), and BBSRC (BB/J004243/1). This work was supported by grants from Bloodwise (12052), MRC (MR/
K021192/1, MR/N000919/1 and MC PC 15079), and NIHR UK (RP-PG-0310-10003).
14 iScience 23, 100989, April 24, 2020
AUTHOR CONTRIBUTIONS
G.F. designed and performed experiments, interpreted the data, and wrote the paper; K.V. performed the
ATAC-seq experiments and wrote the paper; W.C. analyzedmicroarray data and ATAC-seq data and wrote
the paper; A.W. performed part of flow cytometry experiments; Z.N. analyzed microarray data; S.K. per-
formed gene expression analysis; G.A. advised on experiments and edited the paper; P.M. and F.E.C. in-
terpreted the data, supervised the study, and wrote the paper.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: September 3, 2019
Revised: December 9, 2019
Accepted: March 11, 2020
Published: April 24, 2020
REFERENCES
Beijer, M., Molenaar, R., Goversek, G., Mebius,
R.E., Kraal, G., and den Haan, J.M. (2013). A
crucial role for retinoic acid in the development of
Notch-dependent murine splenic CD8- CD4- and
CD4+ dendritic cells. Eur. J. Immunol. 43,
1608–1616.
Blanpain, C., and Fuch, E. (2014). Stem cell
plasticity. Plasticity of epithelial stem cells in
tissue regeneration. Science 344, 1242281.
Christensen, J.E., Andreasen, S.O., Christensen,
J.P., and Thomsen, A.R. (2001). CD11b expression
as a marker to distinguish between recently
activated effector CD8+ T cells and memory cells.
Int. Immunol. 13, 593–600.
Cieri, N., Camisa, B., Cocchiarella, F., Forcato, M.,
Oliveira, G., Provasi, E., Bondanza, A., Bordignon,
C., Peccatori, J., Ciceri, F., et al. (2013). IL-7 and IL-
15 instruct the generation of human memory
stem T cells from naive precursors. Blood 121,
573–584.
Cieri, N., Oliveira, G., Greco, R., Forcato, M.,
Taccioli, C., Cianciotti, B., Valtolina, V., Noviello,
M., Vago, L., Bondanza, A., et al. (2015).
Generation of human memory stem T cells after
haploidentical T-replete hematopoietic stem cell
transplantation. Blood 125, 2865–2874.
Cole, K.E., Strick, C.A., Paradis, T.J., Ogborne,
K.T., Loetscher, M., Gladue, R.P., Lin, W., Boyd,
J.G., Moser, B., Wood, D.E., et al. (1998).
Interferon-inducible T cell alpha chemoattractant
(I-TAC): a novel non-ELR CXC chemokine with
potent activity on activated T cells through
selective high affinity binding to CXCR3. J. Exp.
Med. 187, 2009–2021.
den Braber, I., Mugwagwa, T., Vrisekoop, N.,
Westera, L., Mo¨gling, R., de Boer, A.B., Willems,
N., Schrijver, E.H., Spierenburg, G., Gaiser, K.,
et al. (2012). Maintenance of peripheral naive
T cells is sustained by thymus output in mice but
not humans. Immunity 36, 288–297.
Ellefsen, K., Harari, A., Champagne, P., Bart, P.A.,
Se´kaly, R.P., and Pantaleo, G. (2002). Distribution
and functional analysis of memory antiviral CD8
T cell responses in HIV-1 and cytomegalovirus
infections. Eur. J. Immunol. 32, 3756–3764.
Frumento, G., Zheng, Y., Aubert, G., Raeiszadeh,
M., Lansdorp, P.M., Moss, P., Lee, S.P., and Chen,
F.E. (2013). Cord blood T cells retain early
differentiation phenotype suitable for
immunotherapy after TCR gene transfer to confer
EBV specificity. Am. J. Transpl. 13, 45–55.
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C.M.,
Quigley, M.F., Almeida, J.R., Gostick, E., Yu, Z.,
Carpenito, C., et al. (2011). A human memory
T cell subset with stem cell-like properties. Nat.
Med. 17, 1290–1297.
Gattinoni, L., Klebanoff, C.A., and Restifo, N.P.
(2012). Paths to stemness: building the ultimate
antitumour T cell. Nat. Rev. Cancer 12, 671–684.
Gattinoni, L., Speiser, D.E., Lichterfeld, M., and
Bonini, C. (2017). T memory stem cells in health
and disease. Nat. Med. 23, 18–27.
Gil, M.P., Salomon, R., Louten, J., and Biron, C.A.
(2006). Modulation of STAT1 protein levels: a
mechanism shaping CD8 T-cell responses in vivo.
Blood 107, 987–993.
Hakim, F.T., Memon, S.A., Cepeda, R., Jones,
E.C., Chow, C.K., Kasten-Sportes, C., Odom, J.,
Vance, B.A., Christensen, B.L., Mackall, C.L., et al.
(2005). Age-dependent incidence, time course,
and consequences of thymic renewal in adults.
J. Clin. Invest. 115, 930–939.
Hendriks, J., Xiao, Y., and Borst, J. (2003). CD27
promotes survival of activated T cells and
complements CD28 in generation and
establishment of the effector T cell pool. J. Exp.
Med. 198, 1369–1380.
Henning, A.N., Roychoudhuri, R., and Restifo,
N.P. (2018). Epigenetic control of CD8+ T cell
differentiation. Nat. Rev. Immunol. 18, 340–356.
Hermiston, M.L., Xu, Z., and Weiss, A. (2003).
CD45: a critical regulator of signaling thresholds
in immune cells. Annu. Rev. Immunol. 21,
107–137.
Hinrichs, C.S., Borman, Z.A., Gattinoni, L., Yu, Z.,
Burns, W.R., Huang, J., Klebanoff, C.A., Johnson,
L.A., Kerkar, S.P., Yang, S., et al. (2011). Human
effector CD8+ T cells derived from naive rather
than memory subsets possess superior traits for
adoptive immunotherapy. Blood 117, 808–814.
Hong, C., Luckey, M.A., and Park, J.H. (2012).
Intrathymic IL-7: the where, when, and why of IL-7
signaling during T cell development. Semin.
Immunol. 24, 151–158.
Huang, H.Y., and Luther, S.A. (2012). Expression
and function of interleukin-7 in secondary and
tertiary lymphoid organs. Semin. Immunol. 24,
175–189.
Irles, C., Symons, A., Michel, F., Bakker, T.R., van
der Merwe, P.A., and Acuto, O. (2003). CD45
ectodomain controls interaction with GEMs and
Lck activity for optimal TCR signaling. Nat.
Immunol. 4, 189–197.
Ishida, Y., Agata, Y., Shibahara, K., and Honjo, T.
(1992). Induced expression of PD-1, a novel
member of the immunoglobulin gene
superfamily, upon programmed cell death.
EMBO J. 11, 3887–3895.
Kim, E.Y., Priatel, J.J., The, S.J., and The, H.S.
(2006). TNF receptor type 2 (p75) functions as a
costimulator for antigen-driven T cell responses
in vivo. J. Immunol. 176, 1026–1035.
Klebanoff, C.A., Gattinoni, L., and Restifo, N.P.
(2006). CD8+ T-cell memory in tumor immunology
and immunotherapy. Immunol. Rev. 211,
214–224.
Klebanoff, C.A., Gattinoni, L., and Restifo, N.P.
(2011). Sorting through subsets: which T-cell
populations mediate highly effective adoptive
immunotherapy? J. Immunother. 35, 651–660.
Kondo, T., Morita, R., Okuzono, Y., Nakatsukasa,
H., Sekiya, T., Chikuma, S., Shichita, T., Kanamori,
M., Kubo, M., Koga, K., et al. (2017). Notch-
mediated conversion of activated T cells into
stem cell memory-like T cells for adoptive
immunotherapy. Nat. Commun. 8, 15338.
Kondo, T., Imura, Y., Chikuma, S., Hibino, S.,
Omata-Mise, S., Ando, M., Akanuma, T., Iizuka,
M., Sakai, R., Morita, R., et al. (2018). Generation
and application of human induced-stem cell
memory T cells for adoptive immunotherapy.
Cancer Sci. 109, 2130–2140.
Kurachi, M., Barnitz, R.A., Yosef, N., Odorizzi,
P.M., Di Iorio, M.A., Lemieux, M.E., Yates, K.,
Godec, J., Klatt, M.G., Regev, A., et al. (2014). The
iScience 23, 100989, April 24, 2020 15
transcription factor BATF operates as an essential
differentiation checkpoint in early effector CD8+
T cells. Nat. Immunol. 15, 373–383.
Li, M., Yao, D., Zeng, X., Kasakovski, D., Zhang, Y.,
Chen, S., Zha, X., Li, Y., and Xu, L. (2019). Age
related human T cell subset evolution and
senescence. Immun. Ageing 16, 24.
Lugli, E., Dominguez, M.H., Gattinoni, L.,
Chattopadhyay, P.K., Bolton, D.L., Song, K., Klatt,
N.R., Brenchley, J.M., Vaccari, M., Gostick, E.,
et al. (2013). Superior T memory stem cell
persistence supports long-lived T cell memory.
J. Clin. Invest. 123, 594–599.
Mackall, C.L., Fry, T.J., and Gress, R.E. (2011).
Harnessing the biology of IL-7 for therapeutic
application. Nat. Rev. Immunol. 11, 330–342.
Mikucki, M.E., Fisher, D.T., Matsuzaki, J., Skitzki,
J.J., Gaulin, N.B., Muhitch, J.B., Ku, A.W.,
Frelinger, J.G., Odunsi, K., Gajewski, T.F., et al.
(2015). Non-redundant requirement for CXCR3
signalling during tumoricidal T-cell trafficking
across tumour vascular checkpoints. Nat.
Commun. 6, 7458.
Minami, Y., Kono, T., Miyazaki, T., and Taniguchi,
T. (1993). The IL-2 receptor complex: its structure,
function, and target genes. Annu. Rev. Immunol.
11, 245–268.
Moskowitz, D.M., Zhang, D.W., Hu, B., Le Saux, S.,
Yanes, R.E., Ye, Z., Buenrostro, J.D., Weyand,
C.M., Greenleaf, W.J., and Goronzy, J.J. (2017).
Epigenomics of human CD8 T cell differentiation
and aging. Sci. Immunol. 2, eaag0192.
Murray, J.M., Kaufmann, G.R., Hodgkin, P.D.,
Lewin, S.R., Kelleher, A.D., Davenport, M.P., and
Zaunders, J.J. (2003). Naive T cells are maintained
by thymic output in early ages but by proliferation
without phenotypic change after age twenty.
Immunol. Cell. Biol. 81, 487–495.
Nguyen, K.B., Watford, W.T., Salomon, R.,
Hofmann, S.R., Pien, G.C., Morinobu, A., Gadina,
M., O’Shea, J.J., and Biron, C.A. (2002). Critical
role for STAT4 activation by type 1 interferons in
the interferon-gamma response to viral infection.
Science 297, 2063–2066.
O’Shea, J.J., McVicar, D.W., Bailey, T.L., Burns, C.,
and Smyth, M.J. (1992). Activation of human
peripheral blood T lymphocytes by
pharmacological induction of protein-tyrosine
phosphorylation. Proc. Natl. Acad. Sci. U S A 89,
10306–10310.
Park, J.H., Yu, Q., Erman, B., Appelbaum, J.S.,
Montoya-Durango, D., Grimes, H.L., and Singer,
A. (2004). Suppression of IL7Ralpha transcription
by IL-7 and other prosurvival cytokines: a novel
mechanism for maximizing IL-7-dependent T cell
survival. Immunity 21, 289–302.
Peperzak, V., Veraar, E.A., Xiao, Y., Babala, N.,
Thiadens, K., Brugmans, M., and Borst, J. (2013).
CD8+ T cells produce the chemokine CXCL10 in
response to CD27/CD70 costimulation to
promote generation of the CD8+ effector T cell
pool. J. Immunol. 191, 3025–3036.
Pulko, V., Davies, J.S., Martinez, C., Lanteri, M.C.,
Busch, M.P., Diamond, M.S., Knox, K., Bush, E.C.,
Sims, P.A., Sinari, S., et al. (2016). Human memory
T cells with a naive phenotype accumulate with
aging and respond to persistent viruses. Nat.
Immunol. 17, 966–975.
Quigley, M., Pereyra, F., Nilsson, B., Porichis, F.,
Fonseca, C., Eichbaum, Q., Julg, B., Jesneck, J.L.,
Brosnahan, K., Imam, S., et al. (2010).
Transcriptional analysis of HIV-specific CD8+
T cells shows that PD-1 inhibits T cell function by
upregulating BATF. Nat. Med. 16, 1147–1151.
Remmerswaal, E.B., Havenith, S.H., Idu, M.M., van
Leeuwen, E.M., van Donselaar, K.A., Ten Brinke,
A., van der Bom-Baylon, N., Bemelman, F.J., van
Lier, R.A., and Ten Berge, I.J. (2012). Human virus-
specific effector-type T cells accumulate in blood
but not in lymph nodes. Blood 119, 1702–1712.
Sabatino, M., Hu, J., Sommariva, M., Gautam, S.,
Fellowes, V., Hocker, J.D., Dougherty, S., Qin, H.,
Klebanoff, C.A., Fry, T.J., et al. (2016). Generation
of clinical-grade CD19-specific CAR-modified
CD8+ memory stem cells for the treatment of
human B-cell malignancies. Blood 128, 519–528.
Scott-Browne, J.P., Lo´pez-Moyado, I.F., Trifari, S.,
Wong, V., Chavez, L., Rao, A., and Pereira, R.M.
(2016). Dynamic changes in chromatin
accessibility occur in CD8+ T cells responding to
viral infection. Immunity 45, 1327–1340.
Stange, D.E., Koo, B.K., Huch, M., Sibbel, G.,
Basak, O., Lyubimova, A., Kujala, P., Bartfeld, S.,
Koster, J., Geahlen, J.H., et al. (2013).
Differentiated troy(+) chief cells act as reserve
stem cells to generate all lineages of the stomach
epithelium. Cell 155, 357–368.
Surh, C.D., and Sprent, J. (2008). Homeostasis of
naive and memory T cells. Immunity 29, 848–862.
Tata, P.R., Mou, H., Pardo-Saganta, A., Zhao, R.,
Prabhu, M., Law, B.M., Vinarsky, V., Cho, J.L.,
Breton, S., Sahay, A., et al. (2013).
Dedifferentiation of committed epithelial cells
into stem cells in vivo. Nature 503, 218–223.
Thierfelder, W.E., van Deursen, J.M., Yamamoto,
K., Tripp, R.A., Sarawar, S.R., Carson, R.T.,
Sangster, M.Y., Vignali, D.A., Doherty, P.C.,
Grosveld, G.C., et al. (1996). Requirement for
Stat4 in interleukin-12-mediated responses of
natural killer and T cells. Nature 382, 171–174.
Tripathi, P., Kurtulus, S., Wojciechowski, S., Sholl,
A., Hoebe, K., Morris, S.C., Finkelman, F.D.,
Grimes, H.L., and Hildeman, D.A. (2010). STAT5 is
critical to maintain effector CD8+ T cell
responses. J. Immunol. 185, 2116–2124.
Ucar, D., Ma´rquez, E.J., Chung, C.H., Marches, R.,
Rossi, R.J., Uyar, A., Wu, T.C., George, J., Stitzel,
M.L., Palucka, A.K., et al. (2017). The chromatin
accessibility signature of human immune aging
stems from CD8+ T cells. J. Exp. Med. 214,
3123–3144.
Vranjkovic, A., Crawley, A.M., Gee, K., Kumar, A.,
and Angel, J.B. (2007). IL-7 decreases IL-7
receptor alpha (CD127) expression and induces
the shedding of CD127 by human CD8+ T cells.
Int. Immunol. 19, 1329–1339.
Wherry, E.J. (2011). T cell exhaustion. Nat.
Immunol. 12, 492–499.
Wherry, E.J., Teichgra¨ber, V., Becker, T.C.,
Masopust, D., Kaech, S.M., Antia, R., von Andrian,
U.H., and Ahmed, R. (2003). Lineage relationship
and protective immunity of memory CD8 T cell
subsets. Nat. Immunol. 4, 225–234.
Zanon, V., Pilipow, K., Scamardella, E., De Paoli,
F., De Simone, G., Price, D.A., Martinez Usatorre,
A., Romero, P., Mavilio, D., Roberto, A., et al.
(2017). Curtailed T-cell activation curbs effector
differentiation and generates CD8+ T cells with a
naturally-occurring memory stem cell phenotype.
Eur. J. Immunol. 47, 1468–1476.
Zehnder, J.L., Hirai, K., Shatsky, M., McGregor,
J.L., Levitt, L.J., and Leung, L.L. (1992). The cell
adhesion molecule CD31 is phosphorylated after
cell activation. Down-regulation of CD31 in
activated T lymphocytes. J. Biol. Chem. 267,
5243–5249.
16 iScience 23, 100989, April 24, 2020
iScience, Volume 23
Supplemental Information
Homeostatic Cytokines Drive Epigenetic
Reprogramming of Activated T Cells
into a “Naive-Memory” Phenotype
Guido Frumento, Kriti Verma, Wayne Croft, Andrea White, Jianmin Zuo, Zsuzsanna
Nagy, Stephen Kissane, Graham Anderson, Paul Moss, and Frederick E. Chen
 SUPPLEMENTAL INFORMATION 
 
 
 
                                                  
    
                           
                               
Figure S1. The basal phenotype of TN and TNrev from CB and PB, Related to Figures 1 and 2. (A) 
The expression of CD27, CD45RO and CD62L in TNrev. The expression is shown for the cells 
having undergone phenotype reversion in Figure 1A, right panel. Dashed lines show the 
profiles of isotype controls. (B) The basal phenotype of TN from CB and PB is shown. 
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Figure S2. Pathways significantly enriched in chromatin sites preferentially open in TN from PB 
or CB, Related to Figure 2. (A) Selected significant (FDR<0.1) enrichments of GO terms 
(Biological Process) from DAC-associated gene annotations for DAC sites open in Cord TN cells. 
No significant functional enrichments could be found at the sites preferentially open in 
samples from adults. Results are from 3 CB and 3 PB samples. (B) . Differential accessibility of 
peak regions identified in PB TN cells vs CB TN cells. The x-axes indicates Log2 fold change and 
the y-axes indicates –Log10 p-value of all peaks. Colored points indicate differentially 
accessible chromatin sites with inaccessible sites as blue and accessible sites as red. Points in 
pink are differentially accessible regions annotated as regulatory sites for genes in the 
biological process GO term T cell receptor signalling.   
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Figure S3. Extended screening for putative markers of TNrev, related to Figure 3. The membrane 
expression of non-discriminatory markers in TN, recently reverted TNrev and recently differentiated 
TCM is shown. Single representative experiment out of three. 
  
 
 
 
 
 
 
 
 
 
 
 
    
 
Figure S4. In tonsils, putative TNrev and memory CD8+ T cells differ in the expression of CD95 and 
integrin 7, Related to Figure 3. In the left panel the expression of the two markers is shown 
for CCR7+/CD45RA+ CD8+ T cells; in the right panel the expression of CD95 and integrin 7 in 
memory CD8+ T cells, either CCR7+/CD45RA-, CCR7-/CD45RA- or CCR7-/CD45RA+, is 
superimposed. In purple the classical TN, in black the putative TNrev, and in pale blue the 
memory cells. Single representative experiment out of seven. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
                                                          
 
Figure S5. ATAC-seq signal tracks at selected genes confirming the purity of the samples, related 
to Figure 4. Gene diagrams (bottom) show alternative transcripts with black boxes indicating 
exons. Each subset signal is aggregated across the constituent samples, n = 4(TN), 3(TCM), 
3(TEM), 4(TNrev). The y-axes are in units of reads per million mapped reads.  
 
 
 
 
 
 
 
 
 
                                   
                             
 
Figure S6. Comparison of chromatin landscape in TN, TCM, TEM and TNrev, Related to Figure 4. (A) 
Peak sites that were differentially accessible in at least one pairwise comparison. Shown are 
normalized mapped read density (RPKM) of aggregated TN (n=4), TCM (n=3) , TEM (n=3)  and TNrev 
(n=4) mapped ATAC-seq reads at differentially accessible chromatin sites (centred on peak 
summit, extended +/- 5kbp). (B) DACs counts for accessible and inaccessible sites are shown 
for TCM, TEM and TNrev in comparison to TN. 
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Figure S7. Transcriptomes of TNrev compared TMem cells, Related to Figure 6. Gene expression 
analysis was performed by RNAseq on 3 CD8+ TNrev samples, and 4 CD8+ TMem (2 TCM and 2 TEM) 
samples. (A) PCA plot of all samples. Pairwise comparisons of gene expression in TNrev  vs TCM 
cells (B) and TNrev vs TEM (C) show –Log10 p-value vs Log2 fold change of all genes. Colored 
points indicate differentially expressed genes that are down-regulated (blue) and up-regulated 
(orange) in TNrev. 
 
 
 
  
Figure S8. Stemness transcription factors of interest, Related to Figure 7. Normalized expression 
from RNA-seq of TCM, TEM and TNrev cells. Padj = p value adjusted for multiple testing from 
differential expression analysis of TNrev  vs TCM and TEM cells. Key Transcription factors with 
known increased (A) and decreased (B) expression. 
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 Table S1. Cell numbers are not altered by phenotypic reversion, Related to Figure 1.  
 
 
 
A Absolute number of CD8+ T cells within different subsets at TN nadir (days 6 and 8) 
and TNrev plateau (days 16, 18 and 20). Cell counts (x103) from 3 different CB samples, 
enumerated using Trucount beads. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table S2. GREAT analysis, Related to Figure 5. 
  
 
 
216 TNrev accessible sites
NO ENRICHMENT
401 TNrev and TEM accessible sites
NO ENRICHMENT
890 TEM accessible sites
NO ENRICHMENT
546 TNrev inaccessible sites
 Binom Rank  Binom Raw P-Value   Binom FDR Q-Val  
Signaling events mediated by focal adhesion kinase 2 2.16441E-06 0.001428513
Signaling events mediated by Hepatocyte GF Receptor (c-Met) 3 2.50412E-06 0.001101811
T Cytotoxic Cell Surface Molecules 5 1.64991E-05 0.004355768
Keratinocyte Differentiation 7 0.000126032 0.023766053
PDGFR-beta signaling pathway 10 0.000228715 0.03019034
HIF-1-alpha transcription factor network 15 0.000471389 0.041482267
1648 TNrev and TEM inaccessible sites
 Binom Rank  Binom Raw P-Value   Binom FDR Q-Val  
TCR signaling in naive CD4+ T cells 1 2.46E-27 3.24E-24
Genes involved in Immune System 2 3.81E-26 2.51E-23
TCR signaling in naive CD8+ T cells 3 1.18E-22 5.18E-20
T cell receptor signaling pathway 4 4.57E-21 1.51E-18
Thromboxane A2 receptor signaling 5 2.33E-18 6.14E-16
Genes involved in Generation of second messenger molecules 6 3.36E-17 7.40E-15
Keratinocyte Differentiation 7 5.08E-17 9.58E-15
CXCR4-mediated signaling events 8 7.31E-17 1.21E-14
Genes involved in TCR signaling 9 2.35E-15 3.44E-13
Genes involved in Adaptive Immune System 10 2.23E-14 2.94E-12
T Cell Signal Transduction 11 7.59E-14 9.10E-12
Genes involved in Platelet activation, signaling and aggregation 12 5.48E-13 6.03E-11
HIF-1-alpha transcription factor network 13 2.49E-11 2.53E-09
Signaling events mediated by VEGFR1 and VEGFR2 14 5.20E-11 4.90E-09
Genes involved in Cytokine Signaling in Immune system 15 1.64E-10 1.44E-08
Signaling events mediated by focal adhesion kinase 16 2.42E-10 2.00E-08
Genes involved in Lipoprotein metabolism 17 3.53E-10 2.74E-08
Role of Calcineurin-dependent NFAT signaling in lymphocytes 19 7.14E-10 4.96E-08
Genes involved in Lipid digestion, mobilization, and transport 21 7.27E-10 4.57E-08
Genes involved in Signaling by NOTCH 22 9.66E-10 5.80E-08
2868 TEM inaccessible sites
 Binom Rank  Binom Raw P-Value   Binom FDR Q-Val  
Genes involved in Adaptive Immune System 2 1.11E-23 7.36E-21
TCR signaling in naive CD4+ T cells 3 1.88E-23 8.28E-21
TCR signaling in naive CD8+ T cells 4 1.89E-21 6.24E-19
T cell receptor signaling pathway 5 9.77E-20 2.58E-17
CXCR4-mediated signaling events 6 8.47E-19 1.86E-16
Class I PI3K signaling events 7 1.36E-17 2.57E-15
Genes involved in TCR signaling 8 8.07E-16 1.33E-13
Natural killer cell mediated cytotoxicity 9 4.53E-15 6.64E-13
Genes involved in Cytokine Signaling in Immune system 10 8.55E-15 1.13E-12
T Cell Receptor Signaling Pathway 11 7.90E-14 9.48E-12
Genes involved in Signaling by the B Cell Receptor (BCR) 12 8.12E-14 8.94E-12
Genes involved in Phosphorylation of CD3 and TCR zeta chains 13 6.23E-13 6.33E-11
IL2-mediated signaling events 15 2.12E-12 1.86E-10
Signaling events mediated by focal adhesion kinase 16 3.08E-12 2.54E-10
Lck and Fyn tyrosine kinases in initiation of TCR Activation 17 6.43E-12 4.99E-10
PDGFR-beta signaling pathway 18 6.77E-12 4.97E-10
IL-7 Signal Transduction 19 3.86E-11 2.68E-09
Downstream signaling in naive CD8+ T cells 20 4.83E-11 3.19E-09
Thromboxane A2 receptor signaling 21 9.06E-11 5.69E-09
Fc-epsilon receptor I signaling in mast cells 22 1.15E-10 6.87E-09
 Table S5.  List of the antibodies used for flow cytometry, Related to Figure 1, Figure 2, Figure 3, Figure 5. 
Antigen/ fluorochrome Clone 
Purchased 
from 
Antigen/ 
fluorochrome 
Clone 
Purchased 
from 
CCR2/PE K036C2 BioLegend CD45RA/Fitc HI100 BD  
CCR7/Fitc G043H7 BD  CD45RA/PE-Cy7 HI100 BD  
CCR7/PE G043H7 R&D CD45RO/BV421 UCHL1 BioLegend 
CCR7/BV605 G043H7 BioLegend CD49d/PE 9F10 eBioscience 
CCR9/PE-Cy7 L053E8 BioLegend CD62L/PE DREG-56 BD  
CD11a/PE HI111 BD  CD69/eFluor 450 FN50 eBioscience 
CD11b/PE ICRF44 BD  CD70/APC 113-16 BioLegend 
CD120b/APC 22235 R&D CD8/Fitc SK1 BD  
CD122/APC TU27 BioLegend CD8/Pacific Blue RPA-T8 BD  
CD127/PE A019D5 BioLegend CD95/APC DX2 BD  
CD14/Pacific Blue TuK4 Invitrogen CXCR3/APC 1C6/CXCR3 BD  
CD14/PerCP 134620 R&D CXCR4/APC 12G5 eBioscience 
CD16/Pacific Blue 3G8 Invitrogen gp130/PE 28126 R&D 
CD16/PerCP 245536 R&D granzyme B/Fitc GB11 BD  
CD19/Pacific Blue SJ25-C1 Invitrogen IL-15Ra/PE JM7A4 BioLegend 
CD19/PerCP 4G7-2E3 R&D Integrin 7/PE 473207 R&D 
CD25/APC-Cy7 M-A251 BD  LT-/PE 359-81-11 BioLegend 
CD27/APC 57703 R&D LY-9/PE hlY-9.1.25 BioLegend 
CD3/PE OKT3 BioLegend PD-1/Fitc  MIH4 BD  
CD3/V500 UCHT1 BD  Perforin/Fitc Dg9 eBioscience 
CD31/APC-eFluor 780 WM-59 eBioscience PTK7/PE 188B Miltenyi 
CD4/Fitc SK3 eBioscience TNFSF10/PE RIK-2 BioLegend 
CD44/PE BJ18 BioLegend TNFSF14/APC 115520 R&D 
      
 
 
 
 
 
 
 
 
 
 
 
 TRANSPARENT METHODS  
Cell separation and culture. 
The study was approved by the National Research Ethics Committee, UK REC no. 11/WM/0315, and by 
the Non-Clinical Issue committee of the NHS Blood and Transplant.  Human CB from anonymized 
collections unsuitable for banking, was provided by the NHS Cord Blood Bank, UK, as Non-Clinical Issue. 
Peripheral blood (PB) was collected from consenting adult healthy blood donors from the NHS Blood 
and Transplant Donor Centre, Birmingham, UK.   
PB mononuclear cells (PBMCs) and CBMCs were obtained by Ficoll separation. CD8+ TN and TNrev were 
enriched using the Naïve CD8+ T cell Isolation Kit (Miltenyi Biotech, Bergisch Gladbach, Germany). CD8+ 
TEM cells were negatively isolated after activation of enriched CD8+ TN by removal of CCR7+ and CD45RA+ 
cells with anti-CCR7-APC, anti-CD45RA-APC and anti-APC MicroBeads (Miltenyi). CD8+ TCM cells were 
isolated from less differentiated samples by depletion of CD45RA+ cells with anti CD45RA-APC and anti-
APC MicroBeads. Cells were cultured in RPMI 1640 plus 10% FCS. CD4+ TN cells were isolated with the 
Naïve CD4+ T cell Isolation Cell Isolation Kit II (Miltenyi). 
CD8+ TCM/EM cells were negatively isolated from CD8+ TN cells isolated as indicated above by removal of 
CD45RA+ cells with anti-CD45RA-APC and anti-APC MicroBeads (Miltenyi). 
Dendritic cells (DCs) were generated from adherent mononuclear cells after incubating in plates for 2 
hours. Adherent cells were cultured in the medium supplemented on days 0, 3 and 6 with 50 ng/ml 
GMCSF and 500 U/ml IL-4. On day 6, DCs were matured by adding 2 ng/ml IL-1β, 1000 U/ml IL-6 and 
10 ng/ml TNFα (all from R&D Systems, Minneapolis, USA) (1997). DCs were recovered after a further 
48 hours. 
Mononuclear cells from tonsils were kindly provided by P Murray and E Nagy. Tonsils were obtained 
after tonsillectomy for recurrent acute tonsillitis, minced and dissociated by mechanical means and 
mononuclear cells were collected by Ficoll separation.  
 
 TCR gene transduction. 
CBMCs were retrovirally transduced with a TCR, specific for the HLA A11-restricted SSCSSCPLSK (SSC) 
peptide of the LMP2 protein of Epstein Barr virus, as previously described (Frumento et al, 2013). 
Briefly, cells were transduced with retrovirus 48 hours after activation. The retrovirus used was the 
pMP71-PRE vector (provided by C. Baum, Hannover, Germany) with genes encoding TCR α and β chains 
isolated from an EBV-specific CD8+ T cell clone that targets the HLA A*1101-restricted epitope SSC 
derived from the viral protein LMP2   (Zheng et al., 2015). To generate the retrovirus, Phoenix 
amphotropic packaging cells were transfected with the pMP71-PRE vector using FuGENE HD (Roche, 
Basel, Switzerland). After 48 hours the retroviral supernatant was recovered. Preactivated cells were 
seeded at 4–6 × 106 cells/well in 1 ml RPMI onto 6-well plates coated with retronectin (Takara, Shiga, 
Japan). Retroviral supernatant (1.5 ml/well) or medium alone (mock-transduced) was added to each 
well and centrifuged for 1 h × 800 g at 30°C. Also described are generation of DCs, their loading with 
the peptide, and re-stimulation of transduced T cells with peptide-pulsed DCs. 
Cell activation and treatment. 
Cells were activated, or re-activated, with either of the following stimuli. 
Anti-CD3: cells were incubated with 66 ng/ml anti-CD3 antibody (OKT3), plus 300 U/ml IL-2 (Miltenyi). 
Anti-CD3 and crosslinked anti-CD28: cells were incubated with 66 ng/ml OKT3 plus a mix of 66 ng/ml 
LEAF anti-CD28 (BioLegend, San Diego, CA, USA) and 66 ng/ml rat anti-mouse IgG1 (BioLegend), and 
50 U/ml IL-2. CD3/CD28 beads: Dynabeads T Activator CD3/CD28 (Life Technologies, Grand Island, NY) 
beads were incubated with CBMCs at 1:1 ratio in the presence of 30 U/ml IL-2. PHA: cells were 
incubated with 1% PHA M (Life Technologies, Carlsbad, CA, USA), plus 50 U/ml IL-2. SEB: cells were 
incubated with 1 g/ml SEB (Sigma-Aldrich, St. Louis, MO, USA), plus 50 U/ml IL-2. From day 2, IL-2 100 
U/ml, for stimulation with soluble anti-CD3, or 30 U/ml, for the other cases, was added thrice a week. 
Phenotype was checked thrice a week. When the percentage of CCR7+/CD45RA+ CD8+ T cells dropped 
below 20%, half of the medium was replaced with fresh medium containing either IL-2, IL-4, IL-6, IL-7, 
IL-15 or IL-21 (all from Miltenyi), or combinations thereof, at final concentrations of 30 U/ml, 25 ng/ml, 
 10 ng/ml, 25 ng/ml, 50 ng/ml, and 50 ng/ml, respectively. Thrice a week, half of the culture medium 
was replaced with new medium plus cytokine(s). Re-activation by phorbol myristate acetate (PMA) plus 
ionomycin (Cell Stimulation Cocktail, eBioscience, San Diego, CA, USA) was performed exactly following 
manufacturer’s instructions. BMS 493 (Tocris, Brisol, UK) was preincubated 3 hours before addition of 
IL_7 and/or  all-trans-retinoic acid (ATRA, Sigma Aldrich). 
Flow cytometry. 
The antibodies used for cell membrane staining are listed in Table S5. Gating strategy involved selection 
of single cells and use of a “dump channel” including either 7-aminoactinomycin D (BD, San Jose, CA, 
USA) and PerCP-conjugated anti CD14, CD16 and CD19, or Live/Dead Fixable Violet (Thermo Fisher 
Scientific, Wilminghton, DE, USA) and Pacific Blue-conjugated anti CD14, CD16 and CD19. Proliferation 
was evaluated by staining cells with 1 M CFSE. For intracellular staining, cells were fixed and 
permeabilized using the FIX&PERM kit (ADG, Kaumberg, Austria) or Fixation/Permeabilization 
Solution Kit (BD) for staining of cytokines or TFs, respectively. Indirect staining was carried out 
for E2F-1 (clone 8G9, Novus Biologicals, Littleton, CO, USA) and KAT2B (clone EPR2670, Abcam, 
Cambridge, MA, USA). In this case a PE- conjugated rat anti-mouse IgG1 (clone RMG1-1, BioLegend, 
San Diego, CA, USA) and an APC-conjugated goat ant-rabbit IgG (R&D, Minneapolis, MN, USA) were 
used, respectively. In some experiments cells were enumerated using Trucount Beads (BD). 
Transduced lymphocytes were identified using HLA A*1101:SSC peptide-specific pentamers and 
Tag/PE (Proimmune, Oxford, UK). Flow cytometry was performed on either a FACSCanto II, an LSR II, 
or a Fortressa (BD) flow cytometer. Quantifications were made on the basis of FACSDiva and FlowJo 
(both from BD) softwares. 
Cytotoxicity assay. 
Cytotoxicity of transduced T cells was assessed in a standard 51Cr assay. Briefly, HLA A*1101-transduced 
T2 cells were loaded with the concentrations of SSC peptide indicated in the text, then used as targets 
at 2500 cells/well in a 5 hrs test. 
  ATAC-seq library preparation and analysis 
For sequencing the open chromatin regions in the CD8+ T cell subsets, we used a previously published 
method with slight modification (Brignall et al, 2017). In brief, 50,000 cells were sorted  on a cell sorter 
(FACSAria, BD) and pelleted by centrifugation at 500 × g and 4°C for 10 min. The cell pellet was washed 
once with cold PBS and centrifuged again. Pellets were resuspended in a 50-μl reaction cocktail 
containing 1 μl of 0.5% Digitonin (Promega, Madison, WI, USA), 2.5 μl of Tn5 transposase and 25 μl of 
TD buffer (Nextera DNA library preparation kit, Illumina, San Diego, CA, USA) and incubated for 30 min 
at 37°C with gentle shaking. The tagmented DNA was then purified using Minielute PCR Purification kit 
(Qiagen, Hilden, Germany) and eluted into 11 μl of elution buffer. The  transposed DNA was then 
amplified using  2.5 μl of indexing primers and 25 μl of Nextera PCR master mix according to the PCR 
protocol previously described (Buenrostro et al, 2013). PCR clean-up was then performed using 
AMPure XP beads (Beckman Coulter, Brea, CA, USA), and resuspended in 30 μl of resuspension buffer. 
The libraries were quantified using Qubit fluorometer (Life Technologies), and the size was detemined 
using TapeStation (Agilent, Santa Clara, CA, USA). Sequencing was performed on a High Throughput 
Benchtop NextSeq 500/550 Sequencer using NextSeq® 500/550 High Output Kit v2 - 75 cycles (Illumina, 
San Diego, CA, USA). 
ATAC-seq data was aligned to the human genome (hg19) using Bowtie2 v2.2.9 with the settings: –very-
sensitive-local (Langmead and Salzberg, 2012). Peaks were called on the alignments using MACS2 v2.2 
with settings: --keep-dup=auto –nomodel –shift -100 –extsize 200 (Zang et al, 2008). Peaks were 
annotated with closest gene (by RefSeq transcription start site) and average tag counts (400bp region 
centred on peak summit) using annotatePeaks from HOMER v4.8.  Motif enrichment at peak regions 
was assessed using the HOMER program findMotifsGenome (Heinz et al, 2010).  DACs were identified 
by pairwise comparisons in the R package DESeq2 (Love et al, 2014). Genome-wide average profile 
data at TSS and enhancer sites was obtained using ngs.plot v2.63 (Shen et al, 2014). Heatmaps of DACs 
and mapped read profiles at selected genomic regions were obtained using fluff v2.1.4 (Georgiou et al, 
 2016). ATAC-seq data have been deposited in Gene Expression Omnibus, accession number 
GSE120618, public release December 2018.    
Microarray analysis. 
Gene expression analysis was performed on 3 CD8+ TNrev at day 19 and 3 CD8+ TN samples. RNA 
extraction was performed using RNeasy columns (Qiagen). Source RNA was confirmed as high quality 
by use of a Bioanalyzer 2100 (Agilent). RNA Integrity Numbers of 6.0 were confirmed for all samples 
using a RNA 6000 Pico Chip kit (Agilent). 25ng of each source sample RNA was labeled with Cy3 dye 
using the Low Input Quick Amp Labelling Kit (Agilent). A specific activity of greater than 6.0 was 
confirmed by measurement with a spectrophotometer. 600 ng of labeled RNA was hybridized to 
SurePrint G3 Human 8x60K microarray slides (Agilent). After hybridization, slides were scanned with a 
High Resolution C Scanner (Agilent), using a scan resolution of 3 mm. Feature extraction was performed 
using Feature Extraction Software (Agilent), with no background subtraction. Extracted data were 
normalized using the R 3.4 software environment with the limma 3.32.5 analysis package (Smyth, 
2004). Log transformed expression values were analyzed in limma using a moderated paired t-test. 
Microarray data that support the findings of this study have been deposited in Gene Expression 
Omnibus, accession number GSE114812, public release December 2018.   
RNA-seq analysis 
RNA extraction was performed using RNeasy columns (Qiagen). TruSeq mRNA library preparation and 
sequencing was carried out by Edinburgh Genomics, The University of Edinburgh. Sequencing data 
were generated using NovaSeq 50PE. 
Statistics 
Quantifications of events from flow cytometry were made using FACSDiva and FlowJo (both from BD) 
softwares. 
Genes were classified as differentially expressed if Benjamini-Hochberg adjusted p-value <0.05 and 
absolute fold change >2. Peaks discovered from the ATAC-seq analysis were classified as differentially 
 accessible in a given pairwise comparison if Benjamini-Hochberg adjusted p-value <0.1 and absolute 
log2 fold change >1. Pathway enrichment analysis was performed using G:profiler (Reimand et al, 
2016) with a threshold adjusted p-value of <0.05 for reporting significant enrichments. Gene-set 
enrichment analysis (GSEA) was performed using the Bioconductor R package GAGE (Luo et al, 2009). 
The Hallmark and Canonical Pathways gene sets were downloaded from Molecular Signatures 
Database (MSigDB) (Liberzon et al, 2015). GSEA was also used to assess enrichment of published gene 
signatures for TSCM up/down-regulated vs TN (Gattinoni et al, 2011) and TMNP up/down-regulated vs TN 
(Pulko et al, 2016). TMNP up/down-regulated genes vs TN were extracted from published RNAseq count 
data downloaded from NCBI’s Gene Expression Omnibus (GSE80306). Differentially expressed genes 
(DEGs) with Benjamini-Hochberg adjusted p-value<0.05 and absolute fold change >2 were identified 
using the R package DEseq2. Genomic Regions Enrichment of Annotations Tools (GREAT) (McLean et 
al, 2010) was used to identify functional enrichments within genes annotated as closest to differentially 
accessible chromatin sites. Functional and network analysis was performed on the pool of significant 
genes using Ingenuity Pathway Analysis (Qiagen).  
In all the other cases statistical analysis was carried out using Graph Pad Prism software or Excel 2016.   
Results in graphs are  reported as mean ± 1SD.  
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